2018 Cardiac Dysrhythmia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Cardiac Dysrhythmia Market

  • ID: 4577805
  • Report
  • 70 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • AETAS Pharma Co.,Ltd
  • Armgo Pharma, Inc.
  • Gilead Sciences, Inc.
  • Numerate, Inc.
  • OMEICOS Therapeutics GmbH
  • Sanofi SA
  • MORE
Cardiac Dysrhythmia refers to abnormal rate of heart beats and effects around 6 million people in the US alone. More than 20% of these patients are hospitalized and 8-9% witness death. The pace of heart beat is irregular, or either more than the normal range (tachycardia) or slower than normal (bradycardia). Primary factors contributing to the Cardiac Dysrhythmia condition include diabetes, smoking, stress while symptoms include palpitations, short of breath etc.

To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Cardiac Dysrhythmia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Cardiac Dysrhythmia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Cardiac Dysrhythmia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AETAS Pharma Co.,Ltd
  • Armgo Pharma, Inc.
  • Gilead Sciences, Inc.
  • Numerate, Inc.
  • OMEICOS Therapeutics GmbH
  • Sanofi SA
  • MORE
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Cardiac Dysrhythmia Pipeline Analysis
2.1 Disease and Pipeline Overview
2.2 Cardiac Dysrhythmia Pipeline Snapshot
2.3 Cardiac Dysrhythmia Pipeline by Phase
2.4 Cardiac Dysrhythmia Pipeline by Company
2.5 Cardiac Dysrhythmia Pipeline by Mechanism of Action

3 Cardiac Dysrhythmia- Company Wise Pipeline Analysis
AETAS Pharma Co.,Ltd
Armgo Pharma, Inc.
Beijing CoSci Med-Tech Co.,Ltd
Gilead Sciences, Inc.
HUYA Bioscience International, LLC
InCarda Therapeutics, Inc.
LATITUDE Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
Numerate, Inc.
OMEICOS Therapeutics GmbH
Ono Pharmaceutical Co., Ltd.
Sanofi SA
Servier Laboratories Limited
Sign Path Pharma Inc

4 Cardiac Dysrhythmia R&D Pipeline Snapshots
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 Recent Developments in Cardiac Dysrhythmia Pipeline

6 Appendix
6.1 About the Publisher
6.2 Sources and Research Methodology

Figures
Figure 1: Cardiac Dysrhythmia Pipeline by Phase, H2- 2018
Figure 2: Cardiac Dysrhythmia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Cardiac Dysrhythmia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

Tables
Cardiac Dysrhythmia Pipeline by Phase, H2- 2018
Cardiac Dysrhythmia Pipeline by Companies, H2- 2018
Cardiac Dysrhythmia Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 2: Armgo Pharma, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 4: Gilead Sciences, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 5: HUYA Bioscience International, LLC Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 6: InCarda Therapeutics, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 7: LATITUDE Pharmaceuticals Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 8: Milestone Pharmaceuticals Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 9: Numerate, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 10: OMEICOS Therapeutics GmbH Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 11: Ono Pharmaceutical Co., Ltd. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 12: Sanofi SA Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 13: Servier Laboratories Limited Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 14: Sign Path Pharma Inc Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AETAS Pharma Co.,Ltd
  • Armgo Pharma, Inc.
  • Beijing CoSci Med-Tech Co.,Ltd
  • Gilead Sciences, Inc.
  • HUYA Bioscience International, LLC
  • InCarda Therapeutics, Inc.
  • LATITUDE Pharmaceuticals Inc.
  • Milestone Pharmaceuticals Inc.
  • Numerate, Inc.
  • OMEICOS Therapeutics GmbH
  • Ono Pharmaceutical Co., Ltd.
  • Sanofi SA
  • Servier Laboratories Limited
  • Sign Path Pharma Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll